Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries
Authors' conclusion
Among patients with RA and PsA initiating a bDMARD, the risk of ILD was higher than in the general population, and was highest in RA. MTX comedication was not a risk determinant for ILD.
Study context
- Population
- Patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating a first biologic disease-modifying antirheumatic drug (bDMARD) in 5 Nordic rheumatology registries, without prior interstitial lung disease (ILD), and matched general-population subjects
- Participants
- 29,478 / 10,919 / 362,087
- Exposure
- RA or PsA patients initiating a first bDMARD vs matched general population; Methotrexate (MTX) comedication vs nonuse
- RAn = 29,478
- PsAn = 10,919
- Populationn = 362,087reference
- Outcome
- Incident ILD, assessed through national patient registries
- Follow-up
- Up to 5 years
Methodological detailsregistry-based, 5 Nordic rheumatology registries, matched general population comparators (4 countries), adjusted hazard ratios (HRs)
- Registry-based
- 5 Nordic rheumatology registries
- Matched general population comparators (4 countries)
- Adjusted HRs
Main finding
As reported in the abstract
Incident ILD · up to 5 years
RA
225
events
PsA
23
events
Population
251
events
Each group vs populationAdjusted hazard ratio (95% CI)
RA
9.7(7.97–11.91)
PsA
4.4(2.83–6.97)
Observational data: associations, not effects.
Further findings
| Outcome | Adjusted HR (95% CI) | |
|---|---|---|
| Incident ILD with MTX comedication vs nonuseMTX comedication (RA)vs No MTX (RA) | 1.0 (0.72–1.25) | |
| Incident ILD with MTX comedication vs nonuseMTX comedication (PsA)vs No MTX (PsA) | 0.9 (0.38–2.05) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Original publication
Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries. J Rheumatol. Published 1 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →